Use of retained earnings for capital expenditure and strategic investment
First written in FY2016. 4 of 7 entries say "Advanced", first in FY2024. Latest entry: FY2026.
27 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Capital expenditure during the consolidated fiscal year amounted to ¥11,073 million. Major items included costs for relocating testing facilities at the BML General Research Institute and testing equipment such as automated analyzers.」
In line with its policy of using retained earnings to expand and improve the efficiency of the testing system, the Company invested ¥11,073 million in relocating testing facilities, automated analyzers and other equipment. - FY2025AdvancedAnnual report
「Capital expenditure during the consolidated fiscal year amounted to ¥18,648 million. Major items included construction costs for a new building at the BML General Research Institute, buildings and land related to the construction of pathology and food hygiene laboratories, and testing equipment such as automated analyzers.」
In line with its policy of expanding and improving the efficiency of the testing system and investing for growth, the Company invested ¥18,648 million in next-generation laboratories, pathology and food hygiene laboratories, and testing equipment. - FY2025-H1AdvancedAnnual report
「Net cash used in investing activities was ¥13,380 million, an increase of ¥4,046 million in cash outflows year on year. This was mainly due to a ¥4,069 million increase in payments for the acquisition of property, plant and equipment.」
Payments for the acquisition of property, plant and equipment to expand and improve the efficiency of the testing system and support growth investment amounted to ¥12,352 million, up ¥4,069 million year on year. - FY2024AdvancedAnnual report
「Capital expenditure during the consolidated fiscal year amounted to ¥23,650 million. Major items included construction costs for a new building at the Kawagoe General Research Institute, buildings and land related to the construction of pathology and food hygiene laboratories, and testing equipment such as automated analyzers.」
In line with its policy of expanding and improving the efficiency of the testing system and investing for future growth, the Company invested ¥23,650 million in next-generation laboratories, pathology and food hygiene laboratories, automated analyzers and other equipment. - FY2019RestatedAnnual report
「The Company plans to use retained earnings effectively for capital expenditure to expand and improve the efficiency of its testing system, as well as for strategic investment aimed at future growth.」
The Company continues its policy of using retained earnings to expand and improve the efficiency of the testing system and to make strategic investments for future growth. - FY2017RestatedAnnual report
「The Company plans to use retained earnings effectively for capital expenditure to expand and improve the efficiency of its testing system, as well as for strategic investment aimed at future growth.」
The Company continues its policy of using retained earnings to expand and improve the efficiency of the testing system and to make strategic investments for future growth. - FY2016First statedAnnual report
「The Company plans to use retained earnings effectively for capital expenditure to expand and improve the efficiency of its testing system, as well as for strategic investment aimed at future growth.」
Policy of allocating retained earnings to expanding and improving the efficiency of the testing system and to strategic investment for future growth.